Wed, September 11, 2024
[ 12:00 AM ] - WOPRAI
Wed, May 15, 2024
[ 12:00 AM ] - WOPRAI
Tue, May 14, 2024
[ 12:00 AM ] - WOPRAI
Mon, April 1, 2024
[ 12:00 AM ] - WOPRAI
Thu, March 14, 2024
[ 12:00 AM ] - WOPRAI
Tue, August 15, 2023
[ 12:00 AM ] - WOPRAI
Thu, May 4, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 14, 2023
[ 12:00 AM ] - WOPRAI
Wed, July 13, 2022
[ 12:00 AM ] - WOPRAI
Fri, October 8, 2021
Tue, January 26, 2021
[ 12:00 AM ] - WOPRAI
Wed, January 6, 2021
[ 12:00 AM ] - WOPRAI
Thu, August 6, 2020
[ 12:00 AM ] - WOPRAI
Fri, March 27, 2020
[ 12:00 AM ] - WOPRAI
Wed, February 19, 2020
[ 12:00 AM ] - WOPRAI
Tue, October 1, 2019
[ 12:00 AM ] - WOPRAI
Thu, May 23, 2019
[ 12:00 AM ] - WOPRAI
Benjamin Burnett Maintained (BEAM) at Strong Buy with Increased Target to $69 on, Sep 11th, 2024
Benjamin Burnett of Stifel, Maintained "Beam Therapeutics Inc." (BEAM) at Strong Buy with Increased Target from $66 to $69 on, Sep 11th, 2024.
Benjamin has made no other calls on BEAM in the last 4 months.
There are 4 other peers that have a rating on BEAM. Out of the 4 peers that are also analyzing BEAM, 2 agree with Benjamin's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Gena Wang of "Barclays" Maintained at Hold with Decreased Target to $31 on, Wednesday, August 7th, 2024
- Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $27 on, Wednesday, August 7th, 2024
These are the ratings of the 2 analyists that currently disagree with Benjamin
- Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $80 on, Thursday, August 22nd, 2024
- Eric Joseph of "JP Morgan" Maintained at Buy with Increased Target to $48 on, Wednesday, August 7th, 2024
Contributing Sources